Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$175.00K$175.00Kderived— vs Q4 2023 Net Income-$7.78M-$7.78MderivedN/M vs Q4 2023 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Incomederived-$3,409,000N/M Operating Cash Flowderived-$4,854,000N/M Free Cash Flowderived-$5,064,000N/M Margins · derivedOperating margin-1948.0%
Net margin-4444.6%
ended Jun 30, 2024 · filed Sep 20, 2024 · 82 d after period end